로딩 중…
지수 로딩 중…
Design Therapeutics, Inc.
DSGN· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$12.76+4.76%
2026-08-03
Financials
Valuation Metrics
Design Therapeutics, Inc.'s Market Cap is $797M. At end of 2025 it was $538M. Ranked #2612 of 3,112 in US market (top 84%), #1100 of 1,445 on NASDAQ (top 76%), #204 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 76%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $797M | US#2,612/3,112 Sec#204/269 |
| Revenue | $0.00 | US#2,974/3,112 Sec#204/269 |
| Net Income | $-70M | US—/3,112 Sec—/269 |
| Total Assets | $230M | US#2,957/3,112 Sec#240/269 |
| Net Assets | $218M | US#2,707/3,112 Sec#191/269 |
| Value | ||
| P/B | 3.65x | US#1,890/3,112 Sec#113/269 |
| FCF Yield | -6.79% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -31.97% | US#2,630/3,112 Sec#131/269 |
| ROA | -30.25% | US#2,874/3,112 Sec#163/269 |
| Financial Health | ||
| Debt Ratio | 5.68% | US#56/3,112 Sec#24/269 |
| Total Debt | $3M | US#2,890/3,112 Sec#230/269 |
| FCF | $-54M | US#2,475/3,112 Sec#117/269 |
| Cash | $13M | US#2,920/3,112 Sec#265/269 |
| Current Ratio | 22.28x | US#114/3,112 Sec#27/269 |
| Performance | ||
| 1Y Return | 234.03% | US#86/3,112 Sec#26/269 |
| 1M Return | -18.41% | US#2,922/3,112 Sec#228/269 |
| From 52W High | -26.03% | US#1,990/3,112 Sec#141/269 |
| 1Y MDD | -35.59% | US#1,726/3,112 Sec#115/269 |
| Trading | ||
| Volume | 461,048 shares | US#2,131/3,112 Sec#209/269 |
| Trading Value | $6M | US#2,623/3,112 Sec#216/269 |
| Per Share | ||
| EPS | $-1.22 | US—/3,112 Sec—/269 |
| BPS | $3.71 | US#2,343/3,112 Sec#150/269 |